Interleukin-3 in hematology and oncology: Current state of knowledge and future directions

Cytokines, Cellular and Molecular Therapy

Volumn 5, Issue 2, 1999, Pages 87-95

  Mangi, Manzoor H ^a   Newland, Adrian C ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Bone marrow failure; Bone marrow transplant; Cancer chemotherapy; Immunotherapy; Interleukin 3

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN A; CYTARABINE; DANIPLESTIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 3; INTERLEUKIN 3 RECEPTOR; INTERLEUKIN 3 RECEPTOR AGONIST; INTERLEUKIN 5; LERIDISTIM; LYMPHOCYTE ANTIBODY; MILODISTIM; PROMEGAPOIETIN; RECOMBINANT INTERLEUKIN 3; SC 70935; UNCLASSIFIED DRUG;

APLASTIC ANEMIA; ARTICLE; BLACKFAN DIAMOND ANEMIA; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; BONE PAIN; BREAST CANCER; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG MECHANISM; DRUG TOLERABILITY; EDEMA; EOSINOPHILIA; FEVER; FLU LIKE SYNDROME; GENE TRANSFER; HEADACHE; HEMATOLOGY; HUMAN; IMMUNOMODULATION; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; LYMPHOMA; MEGAKARYOCYTE; META ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID LEUKEMIA; NONHUMAN; ONCOLOGY; OVARY CANCER; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RASH; STROMA CELL; SUBCUTANEOUS DRUG ADMINISTRATION; VASCULITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; BONE MARROW DISEASES; CLINICAL TRIALS; CYTOKINES; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-3; MICE; NEOPLASMS;

EID: 0032809058     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Metcalf D, The molecular control of cell division, differentiation, commitment and maturation. Nature (1989) 339: 27-30.
2. Metcalf D, Hematopoietic regulators: redundancy or subtlety? Blood (1993) 82: 3515-23.
3. Ogawa M, Hematopoiesis. J Allergy Clin Immunol (1994) 94: 645-50.
4. Hirayama F, Ogawa M, Cytokine regulation of early lymphohematopoietic development. Stem Cells (1996) 4: 369-75.
5. Fraser JK, Lill MC, Figlin RA, The biology of cytokine sequence cascade. Semin Oncol (1996) 23(Suppl 4): 2-8.
6. Ihle JN, Interleukin-3 and hematopoiesis. Chem Immunol (1992) 51: 65-106.
7. Takai S, Yamada K, Hirayama N et al, Mapping of the human gene encoding the mutual signal-transducing subunit (beta chain) of granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin 3 (IL-3) and interleukin 5 (IL-5) receptor complexes to chromosome 22q13.1. Hum Genet (1994) 93: 198-200.
8. Nicola NA, Receptors for colony stimulating factors. Br J Haematol (1991) 77: 133-8.
9. Hara T, Miyajima A, Functional and signal transduction mediated by the interleukin-3 receptor system. Stem Cells (1996) 14: 605-18.
10. Nicola NA, Why do hematopoietic growth factor receptors interact with each other? Immunol Today (1987) 8: 134-9.
11. Nicola NA, Metcalf D, Subunit promiscuity among hemopoietic growth factor receptors. Cell (1991) 67: 1-4.
12. Metcalf D, Begley CG, Johnson GR et al, Effects of purified bacterially synthesised murine multi CSF (IL3) on hematopoiesis in normal adult mice. Blood (1986) 68: 46-57.
13. Anglietta M, Sanavio F, Stacchini A, Fubini A, Interleukin 3 in vivo: kinetic response of target cells. Blood (1993) 82: 2054-61.
14. Donahue RE, Sectra J, Metzger M et al, Human interleukin 3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science (1998) 241: 1820-3.
15. Geissler K, Valent P, Bettelheim P et al, In vivo synergism of recombinant human interleukin-3 and recombinant human interleukin-6 on thrombopoiesis in primates. Blood (1992) 79: 1155-60.
16. Van Gils, Westerman Y, Visser TP et al, Neutralising antibodies during treatment of homologous non-glycosylated IL-3 in rhesus monkeys. Leukemia (1994) 8: 846-51.
17. Ganser A, Lindemann A, Seipelt G, Clinical effects of recombinant human interleukin 3. Am J Clin Oncol (1991) 14(Suppl 1): S51-63.
18. Garnick MB, O'Reilly RJ, Clinical promise of new hematopoietic growth factors: M-CSF, IL3 and IL6. Hematol Oncol Clin North Am (1989) 3: 495-509.
19. Yang YC, Clark SC, Interleukin-3: molecular biology and biologic activities. Hematol Oncol Clin North Am (1989) 3: 441-52.
20. Lindmann A, Mertelsmann R, Interleukin-3 structure and function. Cancer Invest (1993) 11: 609-23.
21. Oster W, Schulz G, IL-3: biological and clinical effects. Int J Cell Cloning (1991) 9: 5-23.
22. Newland AC, Is interleukin 3 active in anticancer drug-induced thrombocytopenia? Cancer Chemother Pharmacol (1996) 8(Suppl): S83-8.
23. Biesma B, Pokorny R, Kovarik JM et al, Pharmacokinetics of human interleukin-3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer. Cancer Res (1993) 53: 5915-19.
24. Hovgaard DJ, Folke M, Mortensen BT, NIssen NI, Recombinant human interleukin-3: pharmacokinetics after intravenous and subcutaneous bolus injection and effects on granulocyte kinetics. Br J Haematol (1994) 87: 700-7.
25. Ganser A, Ottman OG, Hoelzer D, IL-3 and IL-3/GM-CSF combination therapy - clinical implications. Stem Cells (1993) 11: 465-73.
26. Ganser A, Lindemann A, Seipelt G et al, Effects of recombinant IL-3 in aplastic anemia. Blood (1990) 76: 1287-92.
27. Bargetzi MJ, Gluckman E, Tichelli A et al, Recombinant IL-3 in refractory severe aplastic anaemia: a phase I/II trial. Br J Haematol (1995) 91: 306-12.
28. Nimer SD, Paquette RL, Ireland P et al, A phase I/II study of IL-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol (1994) 22: 875-80.
29. Gibson FM, Scopes J, Daly S et al, In vitro response of normal and aplastic anaemia bone marrow to mast cell growth factor and in combination with GM-CSF and IL 3. Exp Hematol (1994) 22: 302-12.
30. Geissler K, Forstinger C, Kalhs P et al, Effects of IL-3 on responsiveness to GM-CSF in severe aplastic anaemia. Ann Intern Med (1992) 117: 223-5.
31. Raghavachar A, Ganse A, Freund M et al, Long term IL-3 and intensive immunosuppression in the treatment of aplastic anemia. Cytokines Mol Ther (1996) 2: 215-23.
32. Diamond L, Wang WC, Alter BP, Congenital hypoplastic anemia. Adv Pediatr (1976) 22: 349-78.
33. McGuckin CP, Uhr MR, Gordon-Smith EC, Diamond Blackfan anaemia: three patterns of in vitro response to hemopoietic growth factors. Br J Haematol (1995) 89: 457-64.
34. Gillio AP, Faulkner LB, Alter BP et al, Treatment of Diamond-Blackfan anemia with recombinant human interleukin-3. Blood (1993) 82: 744-51.
35. McGuckin CP, Uhr MR, Ball SE, Gordon-Smith EC, In vitro progenitor analysis in a Diamond-Blackfan anaemia patient who responded once but not twice to IL-3 therapy, using short term and long term culture and c-kit analysis. Br J Haematol (1996) 93: 319-25.
36. Ball SE, Tchernia G, Wranne L et al, Is there a role of IL-3 in Diamond-Blackfan anaemia? Br J Haematol (1995) 91: 313-18.
37. Dunbar CE, Smith D, Kimball J et al, Treatment of Diamond Blackfan anaemia with haematopoietic growth factors, GM-CSF and IL-3: sustained remission following IL-3. Br J Haematol (1991) 79: 316-21.
38. Olivieri NF, Feig SA, Valentino L et al, Failure of recombinant IL-3 therapy to induce erythropoiesis in patients with refractory Diamond-Blackfan anemia. Blood (1994) 83: 2444-50.
39. Freedman MH, Erythropoiesis in Diamond-Blackfan anemia and the role of IL-3 and Steel factor. Stem Cells (1993) 11: 98-104.
40. Guinan EC, Lee YS, Lopez KD et al, Effects of IL-3 and GM-CSF on thrombopoiesis in congenital amegakaryocytic thrombocytopenia. Blood (1993) 81: 1691-8.
41. Kaushansky K, Lok S, Holly RD et al, Promotion of megakaryocytic progenitor expansion and differentiation by the c-MPL ligand thrombopoietin. Nature (1994) 369: 568-71.
42. Andrews RJ, Winkler A, Myerson D et al, Recombinant human ligand for MPL, megakaryocyte growth and development factor (MDGF), stimulates thrombopoiesis in vivo in normal and myelo-suppressed baboons. Stem Cells (1996) 14: 651-60.
43. Scadden DT, Levine JD, Bresnathan J et al, In vivo effects of IL-3 in HIV type I infected patients with cytopenia. AIDS Res Hum Retroviruses (1995) 11: 731-40.
44. Ganser A, Seipelt G, Lindemann A et al, Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood (1990) 6: 455-62.
45. Ganser A, Ottmann OG, Speipelt G et al, Effects of long term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia (1993) 7: 696-701.
46. Ganser A, Janssen JWG, Ottmann OG et al, In vivo effects of GM-CSF and IL-3 on clonal and non-clonal cell populations in patients with clonal hematopoietic disorder. Leukemia (1991) 5: 487-92.
47. Gerhartz HH, Zwierzina HH, Walther J et al, IL-3 plus low doses of cytosine arabinoside (LD-AraC) for the treatment of advanced myelodysplasia. A pilot study of EORTC Leukemia Group. Cancer Invest (1996) 14: 299-306.
48. Hansen PB, Penkowa M, Johnsen HE, Hematopoietic growth factors for the treatment of myelodysplastic syndromes. Leuk Lymphoma (1998) 28: 491-500.
49. Gerhartz HH, Walther J, Neuwirtova R et al, Randomized 3-armed phase III study of IL-3 or GM-CSF as an adjuvant to low doses of cytosine arabinoside (LD-AraC) for the treatment of high risk myelodsplastic syndromes. Blood (1996) 88: 580a.
50. Skipper HE, Criteria associated with destruction of leukemia and solid tumors in experimental animals. Cancer Res (1967) 27: 2636-45.
51. DeVita VT, Principles of chemotherapy. In: Cancer: Principles and Practice of Oncology (ed VT DeVita, S Hellman, SA Rosenberg) 276-300. JB Lippincott, Philadelphia, 1989.
52. Frei E, Canellos G, Dose, a critical factor in cancer chemotherapy. Am J Med (1980) 69: 585-94.
53. D'Hondt V, Weynants P, Humblet Y et al, Dose dependent IL-3 stimulation of thrombopoiesis and neutropoiesis in patients with small cell lung carcinoma before and following chemotherapy: a placebo controlled randomized phase Ib study. J Clin Oncol (1993) 11: 2063-71.
54. Younes A, Sarris A, Consoli U et al, A pilot study of high dose IL-3 treatment of relapsed follicular small cleaved cell lymphoma: hematologic, immunologic and clinical results. Blood (1996) 87: 1698-703.
55. Dercksen MW, Hoekman K, Bokkel T et al, Effects of interleukin 3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours. Br J Cancer (1993) 68: 996-1003.
56. Biesma B, Willemse PHB, Mulder NH, Effects of interleukin 3 after chemotherapy for advanced ovarian cancer. Blood (1992) 80: 1141-8.
57. 2) cyclophosphamide cancer therapy. Ann Oncol (1993) 4: 759-66.
58. Raemakers J, van Imhoff G, Verdonck L et al, The tolerability of continuous intravenous infusion of interleukin 3 after DHAP chemotherapy in patients with relapsed malignant lymphoma: a phase I study. Am J Hematol (1993) 67: 175-81.
59. Hoffman R, Interleukin 3: a potential useful agent for treating chemotherapy related thrombocytopenia. J Clin Oncol (1993) 4: 2057-9.
60. Newland AC, The problem of thrombocytopenia and its management. Advanced Drugs (1995) 6: 65-73.
61. Stahl CP, Winton EF, Monroe MO, Differential effects of sequential, simultaneous and single agent interleukin 3 and granulocyte macrophage colony stimulating factors in megakaryocyte maturation and platelet response in primates. Blood (1992) 80: 2479-85.
62. Giessler RG, Schulte P, Ganser A, Clinical use of hematopoietic growth factors in patients with myelodysplastic syndromes. Int J Hematol (1997) 65: 339-54.
63. Ellis GK, Hutchins L, Limenez-Martin M et al, Phase III double blind study of PIXY321 vs G-CSF after CEP for breast or ovarian carcinoma. Blood (1996) 88: 449a.
64. Vose JM, Anderson JE, Bierman PJ et al, Phase I/II trials of PIXY 321 to enhance engraftment following autologous bone marrow transplantation. J Clin Oncol (1996) 14: 520-6.
65. Wielenga JJ, Vellenga E, Groenewegen A et al, Recombinant IL-3 in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study. Leukemia (1996) 10: 43-7.
66. Schulman KA, Dorsainvil D, Yabroff KR et al, Prospective evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. IL-3 BMT Team. Bone Marrow Transplant (1998) 21: 607-14.
67. American Society of Clinical Oncology, Update of recommendations for the use of hematopoietic colony stimulating factors: evidence based clinical practice guidelines. J Clin Oncol (1996) 14: 1957-60.
68. Hoelzer D, Hematopoietic growth factors - Not whether, but when and where. N Engl J Med (1997) 336: 1822-3.
69. Guillaume T, D'Hondt V, Symann M, IL-3 and peripheral blood stem cell harvesting. Stem Cells (1993) 11: 173-81.
70. Vose JM, Kessinger A, Bierman PJ et al, The use of rhIL-3 for mobilization of peripheral blood stem cells in previously treated patients with lymphoid malignancies. Int J Cell Cloning (1992) 10: 62-4.
71. Hockner P, Giessler K, Kurz M et al, Potentiation of GM-CSF or G-CSF induced mobilization of circulating progenitor cells by pretreatment with IL-3 and harvest by apheresis. Int J Artif Organs (1993) 16(S-5): 25-9.
72. Heinzinger M, Waller C, Rosensteil A et al, Quality of IL-3 and G-CSF mobilized stem cells in patients with early chronic phase CML. Leukemia (1998) 12: 333-9.
73. Brugger W, Bross K, Frischi J et al, Mobilisation of peripheral blood progenitor cells by sequential administration of interleukin 3 and granulocyte monocyte colony stimulating factor following polychemotherapy with etoposide, ifosfamide and cisplatin. Blood (1992) 79: 1193-200.
74. Crump M, Couture F, Kovacs M et al, Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation. Exp Hematol (1993) 21: 405-10.
75. Nemaunaitis J, Appelbaum FR, Singer JW, Phase I trial with recombinant human interleukin 3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood (1993) 82: 3273-8.
76. Fay JW, Bernstein SH, Recombinant IL-3 and GM-CSF after autologous bone marrow transplantation for malignant lymphoma. Semin Oncol (1996) Suppl 4: 22-7.
77. Sheridan WP, Begley CG, Jutkner CA et al, Effects of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high dose chemotherapy. Lancet (1992) 339: 640-4.
78. Naparstak E, Harden Y, Ben-Shahar M et al, Enhanced marrow recovery by short preincubation of marrow allograft with human recombinant IL-3 and GM-CSF. Blood (1992) 80: 1673-8.
79. Thomas JW, Baum CM, Hood WF et al, Potent IL-3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3. Proc Natl Acad Sci USA (1995) 92: 3779-83.
80. Farese AM, Herodin F, McKearn JP et al, Acceleration of hematopoietic reconstitution with a synthetic cytokine (SC-55494) after radiation induced bone marrow aplasia. Blood (1996) 87: 581-91.
81. Abboud CN, DiPersio JF, Gordon L et al, Phase I/II study to determine the safety and tolerability of SC70935 in patients with relapsed lymphoma receiving ESHAP. Blood (1997) 90(Suppl 1): 173a.
82. Giri JG, Smith WG, Kahn LE et al, Promegapoietin, a chimeric growth factor for megakaryocyte and platelet restoration. Blood (1997) 90(Suppl 1): 580a.
83. Williams SF, Lee WJ, Bender JG et al, Selection and expansion of peripheral blood CD34+ cell transplantation for breast cancer. Blood (1996) 87: 1687-91.
84. Steen R, Morkrid L, Tjonnfjord GE, Egeland T, c-kit ligand combined with GM-CSF and or IL-3 can expand CD34+ hematopoietic progenitor subsets for several weeks in vitro. Stem Cells (1994) 12: 214-24.
85. Serrano F, Varas F, Bernard A, Bueren JA, Accelerated and long-term hematopoietic engraftment in mice transplanted with ex-vivo expanded bone marrow. Bone Marrow Transplant (1994) 14: 855-62.
86. Peters SO, Kittler EL, Ramshaw HS, Quesenberry PJ, Ex-vivo expansion of murine marrow cells with IL-3, IL-6, IL-11 and SCF leads to impaired engraftment in irradiated host. Blood (1996) 87: 30-7.
87. Adelmann M, Schulze D, Osten CV et al, Ex-vivo blood stem cell expansion in liquid culture with cytokine cocktails. Role of thrombopoietin. Blood (1996) 88: 604a.
88. Huang S, Peterson S, Li X et al, Gene transduction of human CD34+ CD38-, HLA-DR+ hematopoietic stem cell/progenitor cells. Blood (1996) 88: 429a.
89. Doa MA, Nolta JA, Inclusion of IL-3 during retroviral-mediated transduction on stromal support does not increases the extent of gene transfer into long term engrafting human hematopoietic progenitors. Cytokines Cell Mol Ther (1997) 3: 81-90.
90. Girolomoni G, Ricciardi-Castagnoli P, Dendritic cells hold promise for immunotherapy. Immunol Today (1997) 18: 102-4.
91. NJ Hart, Dendritic cells: unique leukocyte populations which control the primary immune response. Blood (1997) 90: 3245-87.
92. Steinman RM, The dendritic cell system and its role in immunogenicity. Annu Rev Immunol (1991) 9: 271-96.
93. Caux C, Vanbervliet B, Massacrier C et al, Interleukin 3 cooperates with tumor necrosis factor alpha for the development of human dendritic/Langerhans cells for cord blood CD34+ hematopoietic progenitor cells. Blood (1996) 87: 2376-85.
94. Nair SK, Boczkowski D, Snyder D, Gilboa E, Antigen presenting cells pulsed with unfractional tumor-derived peptides are potent tumor vaccines. Eur J Immunol (1997) 27: 589-97.
95. Hirst WJ, Buggins A, Darling D et al, Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retroviral mediated gene transfer of B7.1. Gene Ther (1997) 4: 691-9.
96. Guinan EC, Gribben JG, Boussiotis VA et al, Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood (1994) 84: 3261-82.